Search Results - "Clewell, Jerry"

Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab) by Tebbey, Paul W, Varga, Amy, Naill, Michael, Clewell, Jerry, Venema, Jaap

“…Humira® (adalimumab) is a recombinant human IgG1 monoclonal antibody (mAb) glycoprotein consisting of 1330 amino acids that is specific for human tumor…”
Get full text

Case‐control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes by Zachry, III, Woodie M., Doan, Quynhchau D., Clewell, Jerry D., Smith, Brien J.

“…Summary Purpose:  Although antiepileptic drugs (AEDs) with multisource generic alternatives are becoming more prevalent, no case‐control studies have been…”
Get full text

Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry by Bergman, Martin J., Zueger, Patrick, Patel, Jayeshkumar, Saffore, Christopher D., Topuria, Ia, Cavanaugh, Cristi, Fang, Siran, Clewell, Jerry, Ogdie, Alexis

“…Background There is limited evidence on the clinical and economic benefit of achieving disease control in psoriatic arthritis (PsA) and ankylosing spondylitis…”
Get full text

Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis by Song, Yan, Betts, Keith A., Lu, Yichen, Singh, Rakesh, Clewell, Jerry, Griffith, Jenny

“…Introduction Patients with psoriatic arthritis (PsA) who receive an initial tumor necrosis factor inhibitor (TNFi) may switch to another TNFi or a non-TNFi…”
Get full text

Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics by Citrome, Leslie L, Holt, Richard IG, Zachry, Woodie M, Clewell, Jerry D, Orth, Paul A, Karagianis, Jamie L, Hoffmann, Vicki Poole

“…Background: Type 2 diabetes mellitus has been reported during antipsychotic treatment. Objective: To quantify the potential risk of treatment-emergent diabetes…”
Get full text

Direct medical costs for patients seeking emergency care for losses of epilepsy control in a U.S. managed care setting by Zachry, Woodie M, Doan, Quynhchau D, Smith, Brien J, Clewell, Jerry D, Griffith, Jenny M

“…Abstract The objective of this retrospective claims database study was to compare the costs of care from a U.S. payer perspective before and after epilepsy…”
Get full text

Comments to the Editor on “Outcomes and Costs of Risperidone versus Olanzapine in Patients with Chronic Schizophrenia or Schizoaffective Disorders: A Markov Model” by Clewell, Jerry D, Baker, Robert W

Get full text

Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data by Strand, Vibeke, Shah, Ruchitbhai, Atzinger, Chris, Zhou, Jifang, Clewell, Jerry, Ganguli, Arijit, Tundia, Namita

“…Objective: Determine healthcare resource utilization (HCRU) and costs associated with fatigue and stiffness among patients with rheumatoid arthritis (RA)…”
Get full text

Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis by Bergman, Martin, Tundia, Namita, Yang, Min, Orvis, Eli, Clewell, Jerry, Bensimon, Arielle

“…Introduction To compare the economic benefit of upadacitinib combination therapy versus tofacitinib combination therapy and upadacitinib monotherapy versus…”
Get full text

Healthcare Costs of Not Achieving Remission in Patients with Rheumatoid Arthritis in the United States: A Retrospective Cohort Study by Bergman, Martin, Zhou, Lili, Patel, Pankaj, Sawant, Ruta, Clewell, Jerry, Tundia, Namita

“…Introduction To compare all-cause and rheumatoid arthritis (RA)-related healthcare costs and resource use in patients with RA who do not achieve remission…”
Get full text

The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review by Ganguli, Arijit, Clewell, Jerry, Shillington, Alicia C

“…Patient support programs (PSPs), including medication management and counseling, have the potential to improve care in chronic disease states with complex…”
Get full text

Missed opportunities for treatment of inflammatory arthritis and factors associated with non-treatment: An observational cohort study in United States Veterans with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis by Walsh, Jessica A., Pei, Shaobo, Alexander, Swetha, Braaten, Tawnie, Walker, Jodi H., Clewell, Jerry, Douglas, Kevin M., Penmetsa, Gopi K., Ye, Xiangyang, Breviu, Brian, Cannon, Grant W., Kunkel, Gary A., Sauer, Brian C.

“…To identify factors associated with non-treatment with biologic and non-biologic disease modifying anti-rheumatic drugs (DMARDs) during the 12 months after…”
Get full text

Cost-utility analyses of targeted immunomodulators in rheumatoid arthritis: systematic review by Sussman, Matthew, Tao, Charles, Patel, Pankaj, Tundia, Namita, Clewell, Jerry, Menzin, Joseph

“…Cost-utility (CU) modeling is a common technique used to determine whether new treatments represent good value for money. As with any modeling exercise,…”
Get more information

Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars by Desai, Rishi J., Kim, Seoyoung C., Curtis, Jeffrey R., Bosco, Jaclyn L.F., Eichelberger, Bernadette, Barr, Charles E., Lockhart, Catherine M., Bradbury, Brian D., Clewell, Jerry, Cohen, Hillel P., Gagne, Joshua J.

“…Purpose As more biosimilars become available in the United States, postapproval noninterventional studies describing biosimilar switching and comparing…”
Get full text

Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance by Zhang, Jie, Sridhar, Gayathri, Barr, Charles E, Eichelberger, Bernadette, Lockhart, Catherine M, Marshall, James, Clewell, Jerry, Accortt, Neil A, Curtis, Jeffrey R, Holmes, Cynthia, McMahill-Walraven, Cheryl N, Brown, Jeffrey S, Haynes, Kevin

“…There is a need for postmarketing evidence generation for novel biologics and biosimilars. To assess the feasibility, strengths, and limitations of the…”
Get full text

Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis by Walsh, Jessica A, Pei, Shaobo, Penmetsa, Gopi K, Sauer, Brian C, Patil, Vikas, Walker, Jodi H, Clewell, Jerry, Douglas, Kevin M, Clegg, Daniel O, Cannon, Grant W, Halwani, Ahmad

“…Delays in treatment for inflammatory arthritis (IA) are associated with unfavorable outcomes, including impaired quality of life, irreversible joint damage,…”
Get full text

AMCP Partnership Forum: Biosimilars--Ready, Set, Launch

“…Through 2020, reference biologic products will lose patent protection that will be worth $54 billion to the U.S. economy. Consequently, interest in biosimilars…”
Get full text